An Act Permitting Emergency Medical Technicians To Administer Intranasal Glucagon.
Summary
SB 257 would amend Connecticut’s general statutes to allow emergency medical technicians (EMTs) to administer intranasal glucagon. The bill treats intranasal glucagon similarly to an opioid antagonist for purposes of EMT authority, meaning EMTs could use the medication in the field when responding to a medical emergency involving severe hypoglycemia or suspected low blood sugar.
The measure is narrowly focused and does not create a new program or mandate; it expands the list of medications EMTs are authorized to administer. In practical terms, it would give prehospital responders another tool to stabilize patients before they reach a hospital, potentially improving emergency care for people with diabetes or other conditions that can cause dangerous hypoglycemia.
Impact
The bill would change state emergency medical services law by expressly authorizing EMTs to administer intranasal glucagon under the same framework used for opioid antagonists. This would affect EMT practice standards, EMS protocols, and any related training or medical direction requirements governing prehospital medication administration. It would primarily impact patients experiencing severe low blood sugar, as well as EMS agencies and medical directors responsible for implementing field treatment procedures.
Sentiment
Based on the bill text and the absence of recorded committee testimony or votes, the overall sentiment appears neutral to supportive. The proposal is presented as a practical public health and emergency response measure, with no visible opposition in the available record. Because there are no transcripts or vote results, there is no evidence of controversy in the materials provided.
Contention
No specific points of contention are documented in the available committee or voting record. Potential issues that could arise, though not reflected in the provided materials, would likely involve EMT training, scope-of-practice concerns, medical oversight, and whether intranasal glucagon should be treated like other field-administered emergency medications. The bill’s narrow scope suggests limited controversy, but no formal debate is available to confirm that.